Glaukos (GKOS) is rallying after reporting first-quarter 2026 results that topped expectations and showcased accelerating demand for its glaucoma franchise. The company delivered record Q1 net sales of $150.6 million, up 41% year over year (39% in constant currency), and raised its full-year 2026 net sales outlook to $620–$635 million from $600–$620 million. (businesswire.com)

Glaukos posted record glaucoma net sales of $129.3 million in Q1, up 47% year over year, with record U.S. glaucoma net sales of $93.5 million, up 58%. Management pointed to iDose TR and Epioxa as the main growth drivers, and the company exited the quarter with about $280.5 million in cash, cash equivalents, short-term investments and restricted cash, and no debt. (businesswire.com)

The strongest signal in the quarter was iDose TR execution, with iDose contributing about $54 million in Q1 and showing broad-based adoption, including early successful re-administrations. Investors are also watching the Epioxa launch trajectory; Epioxa is commercially available, and its ramp is expected to benefit from a permanent HCPCS J-code (J2789) that becomes effective July 1, 2026, which is designed to streamline reporting and payment over time. (marketbeat.com)

Following the results, bullish sentiment strengthened as analysts highlighted the magnitude of the revenue beat and the raised full-year guide. One firm lifted its price target to $141 after the quarter’s outperformance, flagging stronger-than-expected glaucoma revenue and iDose contribution. The next catalysts are continued iDose TR penetration and evidence that Epioxa adoption and reimbursement improve as payers operationalize the upcoming permanent J-code. (in.investing.com)